These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 32629401)

  • 21. The Role of Prescribing Generic (Non-proprietary) Drugs in the Prevalence of Therapeutic Inertia in Multiple Sclerosis Care.
    Saposnik G; Mamdani M; Terzaghi M; Saladino ML; Silva B; Tobler PN; Caceres F
    Front Neurol; 2018; 9():835. PubMed ID: 30369904
    [No Abstract]   [Full Text] [Related]  

  • 22. Reasons for switching to fingolimod in patients relapsing-remitting multiple sclerosis in France: the ESGILE study.
    Tourbah A; Papeix C; Tourniaire P; Rerat K; Meite M; Durand B; Lamy F; Chouette I; Mekies C;
    Mult Scler Relat Disord; 2020 Nov; 46():102433. PubMed ID: 32862037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidemiology, characteristics and treatment of patients with relapsing remitting multiple sclerosis and incidence of high disease activity: Real world evidence based on German claims data.
    Ohlmeier C; Gothe H; Haas J; Osowski U; Weinhold C; Blauwitz S; Schmedt N; Galetzka W; Berkemeier F; Tackenberg B; Stangel M
    PLoS One; 2020; 15(5):e0231846. PubMed ID: 32357176
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychometric Properties of the SymptoMScreen Questionnaire in a Mild Disability Population of Patients with Relapsing-Remitting Multiple Sclerosis: Quantifying the Patient's Perspective.
    Meca-Lallana J; Maurino J; Hernández-Pérez MÁ; Sempere ÁP; Brieva L; García-Arcelay E; Terzaghi M; Saposnik G; Ballesteros J
    Neurol Ther; 2020 Jun; 9(1):173-179. PubMed ID: 31955391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
    BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatigue in teriflunomide-treated patients with relapsing remitting multiple sclerosis in the real-world Teri-FAST study.
    de Sèze J; Devy R; Planque E; Delabrousse-Mayoux JP; Vandhuick O; Kabir M; Gherib A
    Mult Scler Relat Disord; 2021 Jan; 47():102659. PubMed ID: 33291032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.
    Yano H; Gonzalez C; Healy BC; Glanz BI; Weiner HL; Chitnis T
    Mult Scler Relat Disord; 2019 Oct; 35():119-127. PubMed ID: 31374460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emotional expressions associated with therapeutic inertia in multiple sclerosis care.
    Saposnik G; Oh J; Terzaghi MA; Kostyrko P; Bakdache F; Montoya A; Jaja BNR; Nisenbaum R; Ruff CC; Tobler PN
    Mult Scler Relat Disord; 2019 Sep; 34():17-28. PubMed ID: 31226545
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.
    Tsivgoulis G; Katsanos AH; Grigoriadis N; Hadjigeorgiou GM; Heliopoulos I; Papathanasopoulos P; Kilidireas C; Voumvourakis K; Dardiotis E;
    PLoS One; 2015; 10(12):e0144538. PubMed ID: 26642051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.
    Hurwitz BJ; Jeffery D; Arnason B; Bigley K; Coyle P; Goodin D; Kaba S; Kirzinger S; Lynch S; Mandler R; Mikol D; Rammohan K; Sater R; Sriram S; Thrower B; Boateng F; Jakobs P; Wash MB; Bogumil T
    Clin Ther; 2008 Jun; 30(6):1102-12. PubMed ID: 18640466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis.
    Sato S; Lim J; Miehm JD; Buonaccorsi J; Rajala C; Khalighinejad F; Ionete C; Kent JA; van Emmerik REA
    Mult Scler Relat Disord; 2020 Jun; 41():102031. PubMed ID: 32172213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patient perspective on decisions to switch disease-modifying treatments in relapsing-remitting multiple sclerosis.
    Manzano A; Eskyté I; Ford HL; Pavitt SH; Potrata B; Schmierer K; Chataway J; Webb EJD; Meads D; Pepper G; Bekker HL
    Mult Scler Relat Disord; 2020 Nov; 46():102507. PubMed ID: 32979733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Goretti B; Caniatti L; Di Monte E; Ferrazza P; Brescia Morra V; Lo Fermo S; Picconi O; Luccichenti G;
    Mult Scler; 2009 Jul; 15(7):779-88. PubMed ID: 19542262
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM.
    Fernández Ó; Giovannoni G; Fox RJ; Gold R; Phillips JT; Potts J; Okwuokenye M; Marantz JL
    Clin Ther; 2017 Aug; 39(8):1671-1679. PubMed ID: 28751099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laquinimod for multiple sclerosis.
    He D; Han K; Gao X; Dong S; Chu L; Feng Z; Wu S
    Cochrane Database Syst Rev; 2013 Aug; (8):CD010475. PubMed ID: 23922214
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England.
    Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N
    J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL; Moses H; Calkwood J; Tornatore C; LaGanke C; Smoot KE; Meka V; Okwuokenye M; Hotermans C; Mendoza JP; Mann MK; Meltzer LA
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
    Calabresi PA; Kieseier BC; Arnold DL; Balcer LJ; Boyko A; Pelletier J; Liu S; Zhu Y; Seddighzadeh A; Hung S; Deykin A;
    Lancet Neurol; 2014 Jul; 13(7):657-65. PubMed ID: 24794721
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Summarizing Patient Preferences for the Competitive Landscape of Multiple Sclerosis Treatment Options.
    Jonker MF; Donkers B; Goossens LMA; Hoefman RJ; Jabbarian LJ; de Bekker-Grob EW; Versteegh MM; Harty G; Wong SL
    Med Decis Making; 2020 Feb; 40(2):198-211. PubMed ID: 32065023
    [No Abstract]   [Full Text] [Related]  

  • 40. Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).
    Fernández O; Duran E; Ayuso T; Hernández L; Bonaventura I; Forner M;
    PLoS One; 2017; 12(10):e0185766. PubMed ID: 29049356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.